Mirae Asset Global Investments Co., Ltd. Nurix Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 1,771 shares of NRIX stock, worth $43,814. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,771
Previous 30,904
94.27%
Holding current value
$43,814
Previous $454,000
92.07%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NRIX
# of Institutions
183Shares Held
66.4MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$169 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$109 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$98.7 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$96 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$89.7 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.17B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...